

## **Information Governance**

The Green
1 Roger Dowley Court
Russia Lane
London
E2 9NJ

Telephone: 020 7655 4053 Email elft.foi@nhs.net

Website: <a href="https://www.elft.nhs.uk">https://www.elft.nhs.uk</a>

30th March 2020

Our reference: FOI DA3415

I am responding to your request for information received 11<sup>th</sup> March 2020. This has been treated as a request under the Freedom of Information Act 2000.

I am now enclosing a response which is attached to the end of this letter. Please do not hesitate to contact me on the contact details above if you have any further queries.

Yours sincerely,

Ayomide Adediran
Information Governance Coordinator

If you are dissatisfied with the Trust's response to your FOIA request then you should contact us and we will arrange for an internal review of this decision. If you remain dissatisfied with the decision following our response to your complaint, you may write to the Information Commissioner for a decision under Section 50 of the Freedom of Information Act 2000. The Information Commissioner can be contacted at:

Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Tel: 0303 123 1113 Web: <u>www.ico.org.uk</u>

Please note that the data supplied is not allowed to be re-used and/or published without the explicit consent of East London NHS Foundation Trust. Please contact the signatory to request permission if this is your intention

Chair: Marie Gabriel Chief Executive: Dr Navina Evans

## Request:

Under the terms of the Freedom of Information Act 2000 please provide me with the following information:

Question 1a. Since 1 November 2018, how many applications regarding unlicensed Cannabis-Based Products for Medicinal Use (CBPMs) have been received by your Drug and Therapeutic Committee, or a similar clinical governance body? Please exclude Sativex and Epidiolex.

Answer: Zero.

Question 1b. Please provide the therapeutic indication for the applications received e.g. chronic pain

Answer: Not applicable.

Question1c. Please detail from which department the request originated?

Answer: Not applicable.

Question 2. Of the total number of applications to your Drug and Therapeutic Committee, or a similar clinical governance body, how many applications for unlicensed CBPMs has the Trust declined since 1 November 2018? Please provide any details as to the reason/s behind declining the applications.

Answer: Not applicable.

Question 3a. Of the total number of applications to your Drug and Therapeutic Committee, or a similar clinical governance body, how many applications for unlicensed CBPMs has the Trust accepted since 1 November 2018? Please provide any details of the application accepted where possible, including the cost of reimbursement and the product/s prescribed.

Answer: Not applicable.

Question 3b. Please provide the therapeutic indication for the applications received e.g. chronic pain

Answer: Not applicable.

Question 3c. Please detail from which department the request originated?

Answer: Not applicable.

Question 4. For applications to your Drug and Therapeutic Committee, or a similar clinical governance body, that have been accepted, please advise what the subsequent stage was (if there was one)?

E.g. an Individual Funding Request being submitted or new entries being added to the Trust Formulary.

Answer: Not applicable.

Chair: Marie Gabriel Chief Executive: Dr Navina Evans

Question 5. Please clarify whether funding for unlicensed Cannabis-Based Products for Medicinal Use is at CCG or Trust level?

Answer: Funding for unlicensed cannabis based products for medicinal use is

at Trust level.

Question 6. Please clarify whether your Trust operates a policy with a capped number of prescriptions or duration of prescriptions for unlicensed Cannabis-Based Products for Medicinal Use?

Answer: There is no policy for a capped number of prescriptions or duration of

prescriptions for unlicensed cannabis based products for medicinal use. This is not used in mental health or community health services.

Chair: Marie Gabriel Chief Executive: Dr Navina Evans